Among several advances in SLE research, PPARγ has emerged as a promising target, and the PPARγ agonists pioglitazone and rosiglitazone have yielded hopeful results in mouse models of the disease [82,92]. This evidence concerns the gene PPARG and systemic lupus erythematosus.